FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:727-729 August 21, 2003 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Löwenberg, B. PubMed Citation

Acute myeloid leukemia (AML) is a malignant disease resulting from acquired mutations that block the differentiation of primitive hematopoietic cells and thereby cause immature myeloid precursors to accumulate. The leukemia cells not only have a proliferative advantage, but also suppress the growth and maturation of normal blood cells, resulting in anemia, neutropenia, and thrombocytopenia. AML occurs in patients of all ages, and approximately 35 to 40 percent of younger patients can be cured with intensive chemotherapy. The results are much worse in patients who are older than 60 years of age: only 5 to 10 percent of such patients are . . . [Full Text of this Article]

Source Information

From the Division of Hematology–Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit.

This article has been cited by other articles:

• Palmieri, S., D'Arco, A. M., Celentano, M., Mele, G., Califano, C., Pollio, F., D'Amico, M. R., Ferrara, F. (2006). An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. Ann Oncol 17: 1146-1151 [Abstract] [Full Text]  
• Tallman, M. S., Gilliland, D. G., Rowe, J. M. (2005). Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163 [Abstract] [Full Text]  
• Amadori, S., Suciu, S., Jehn, U., Stasi, R., Thomas, X., Marie, J.-P., Muus, P., Lefrere, F., Berneman, Z., Fillet, G., Denzlinger, C., Willemze, R., Leoni, P., Leone, G., Casini, M., Ricciuti, F., Vignetti, M., Beeldens, F., Mandelli, F., De Witte, T., for the EORTC/GIMEMA Leukemia Groups, (2005). Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106: 27-34 [Abstract] [Full Text]  
• Tallman, M. S. (2005). New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents. ASH Education Book 2005: 143-150 [Abstract] [Full Text]